Skip to main content

Immunotherapy for malignant glioma.

Publication ,  Journal Article
Suryadevara, CM; Verla, T; Sanchez-Perez, L; Reap, EA; Choi, BD; Fecci, PE; Sampson, JH
Published in: Surg Neurol Int
2015

Malignant gliomas (MG) are the most common type of primary malignant brain tumor. Most patients diagnosed with glioblastoma (GBM), the most common and malignant glial tumor, die within 12-15 months. Moreover, conventional treatment, which includes surgery followed by radiation and chemotherapy, can be highly toxic by causing nonspecific damage to healthy brain and other tissues. The shortcomings of standard-of-care have thus created a stimulus for the development of novel therapies that can target central nervous system (CNS)-based tumors specifically and efficiently, while minimizing off-target collateral damage to normal brain. Immunotherapy represents an investigational avenue with the promise of meeting this need, already having demonstrated its potential against B-cell malignancy and solid tumors in clinical trials. T-cell engineering with tumor-specific chimeric antigen receptors (CARs) is one proven approach that aims to redirect autologous patient T-cells to sites of tumor. This platform has evolved dramatically over the past two decades to include an improved construct design, and these modern CARs have only recently been translated into the clinic for brain tumors. We review here emerging immunotherapeutic platforms for the treatment of MG, focusing on the development and application of a CAR-based strategy against GBM.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Surg Neurol Int

DOI

ISSN

2229-5097

Publication Date

2015

Volume

6

Issue

Suppl 1

Start / End Page

S68 / S77

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Suryadevara, C. M., Verla, T., Sanchez-Perez, L., Reap, E. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015). Immunotherapy for malignant glioma. Surg Neurol Int, 6(Suppl 1), S68–S77. https://doi.org/10.4103/2152-7806.151341
Suryadevara, Carter M., Terence Verla, Luis Sanchez-Perez, Elizabeth A. Reap, Bryan D. Choi, Peter E. Fecci, and John H. Sampson. “Immunotherapy for malignant glioma.Surg Neurol Int 6, no. Suppl 1 (2015): S68–77. https://doi.org/10.4103/2152-7806.151341.
Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(Suppl 1):S68–77.
Suryadevara, Carter M., et al. “Immunotherapy for malignant glioma.Surg Neurol Int, vol. 6, no. Suppl 1, 2015, pp. S68–77. Pubmed, doi:10.4103/2152-7806.151341.
Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, Sampson JH. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(Suppl 1):S68–S77.

Published In

Surg Neurol Int

DOI

ISSN

2229-5097

Publication Date

2015

Volume

6

Issue

Suppl 1

Start / End Page

S68 / S77

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences